TG Therapeutics reported $89.8M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 5.8B 1.25B Sep/2026
Ardelyx USD -9.78M 19.98M Jun/2026
Arrowhead Research USD -212.62M 64.94M Sep/2026
Bayer EUR 1.62B 529M Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
Corcept Therapeutics USD 115.75M 73.59M Sep/2026
Curis USD -12.3M 231K Sep/2023
Gilead Sciences USD -9.31B 12.82B Jun/2026
J&J USD 8.99B 721M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Novartis USD 8.62B 2.14B Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
TG Therapeutics USD 89.8M 62.9M Sep/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026